Expanded Access Policy
At this time, our investigational drug neflamapimod is only available through participation in one of our ongoing clinical trials. Neflamapimod is not available on an expanded access basis, including for single patient compassionate use.
Patients who have participated in the AscenD-LB phase 2 clinical trial, are able to receive neflamapimod on an open label basis through the clinical investigator site through which they participated in AscenD-LB.
Resources for Patients and Caregivers
MORE ABOUT THE DISEASE
Lewy Body Dementia Association (LBDA)Alzheimer's Association: Lewy Body Dementia
National Institute on Aging (NIH)
Cleveland Clinic
POLICIES
Expanded Access PolicyFinancial Conflict of Interest Policy
SUPPORT GROUPS
LBDA: Caregiver PacketWell Spouse Association
QUESTIONS ABOUT EIP'S APPROACH
Learn more about our unique approach to reversing the effects of dementia with Lewy bodiesAsk us a question
"The data from the trial of neflamapimod in DLB are very encouraging, setting the stage for more extensive testing. There are no approved treatments for DLB, the second most common cause of neurodegenerative dementia, and there is an urgent need to find therapies for this severe and progressive disorder."
